Total Drugs And Intermediates Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.00 Cr
as on 23-10-2024
- Company Age 18 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.50 Cr
as on 23-10-2024
- Satisfied Charges ₹ 2.28 Cr
as on 23-10-2024
- Revenue 35.07%
(FY 2023)
- Profit -3.79%
(FY 2023)
- Ebitda 11.12%
(FY 2023)
- Net Worth 53.38%
(FY 2023)
- Total Assets 21.25%
(FY 2023)
About Total Drugs And Intermediates
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹11.50 Cr. The company has closed loans amounting to ₹2.28 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sunitha Sathi, Narasimha Enukonda, and Alluru Ashokreddy serve as directors at the Company.
- CIN/LLPIN
U24222TG2006PTC048986
- Company No.
048986
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Feb 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Total Drugs And Intermediates?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narasimha Enukonda  | Managing Director | 01-Jul-2011 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sunitha Sathi | Director | 22-Aug-2022 | Current |
| Alluru Ashokreddy | Director | 01-Jul-2011 | Current |
Financial Performance of Total Drugs And Intermediates.
Total Drugs And Intermediates Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.07% increase. The company also saw a slight decrease in profitability, with a 3.79% decrease in profit. The company's net worth Soared by an impressive increase of 53.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Total Drugs And Intermediates?
In 2023, Total Drugs And Intermediates had a promoter holding of 82.00% and a public holding of 18.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Sep 2022 | ₹6.50 Cr | Open |
Others Creation Date: 20 May 2020 | ₹5.00 Cr | Open |
Indian Overseas Bank Creation Date: 19 Mar 2012 | ₹2.28 Cr | Satisfied |
How Many Employees Work at Total Drugs And Intermediates?
Total Drugs And Intermediates has a workforce of 10 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Total Drugs And Intermediates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Total Drugs And Intermediates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
